Growth Hormone Therapy by Davies, K & Davies, K
Workshop on 
GHD
Kate Davies
Senior Lecturer in Children’s Nursing 
London South Bank University
Introduction
• Different reasons why children need GH in 
comparison to adults
• Confusions re diagnosis and whether to treat
• Case studies
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Case study 1
GHD?
Age 1.61years
March 2010
• Noticed to be short by Practice Nurses
• Referred to Paediatric Endocrinologist
o When did the Practice Nurse refer?
o Who referred to them?
• Parents 
• Health Visitor
• Full history
o SGA
• Auxology
• Parents height
• Baseline bloods
• Follow up in 4 months 
SGA
• SGA
o Small for gestational age
• Weight below 10th
percentile
• AGA
o Weight between 10 and 90th
percentiles (between 2.5kg 
and 4kg)
• LGA
o Weight above 90th percentile
• IUGR
o Deviation in expected growth 
pattern
• Not all IUGR babies are 
SGA
SGA
SGA
• High dose GH therapy for 
a period of 2 years 
induces catch up growth
• Catch down growth has 
been reported if 
treatment is discontinued 
in childhood
• At risk of hypoglycaemia
• GH: 0.035mg/kg/day
• Start at age 4 years
• Cause
o Foetal
• Chromosomal
• Genetic syndromes 
• Intrauterine infection
o Placental
• Impaired function
o Malnutrition
o Hypoxaemia
o Acidaemia
o Maternal
• Chronic illness
o Renal disease
o Hypertension
• Smoking / alcohol / drugs
Age 2.27 years
July 2010
• Baselines all normal
• Decided to watch height velocity
o 8.6cm/yr
• Follow up 4 months
Age 2.61 years
November 2010
• Height velocity now 11.9cm/yr
• Watch and wait
• Follow up 6 months
Age 3.11 years June 2011 
(one year in the system)
• Height velocity 4.6 cm/yr
• More  baseline bloods
o Normal 
• Follow up 6/12
• Still too young for SGA GH treatment
Discussion
• What do you think the appropriate course of action 
is to take now? 
Age 3.63 years
December 2011
• Height velocity 6 cm/yr
• Decision made to undertake Glucagon stimulation 
test
o ? See if GHD 
February 2012
• Glucagon stimulation test
o Brought into the day ward
• Return to clinic when results 
ready
Age 4.15 years
June 2012
(two years in the system)
• Found to be GHD!
• Full range of GH devices shown and demonstrated 
to the child and family
o Licensed indications
o DVDs given to family to take him if indecisive
o CNS contact details given
• Parents called CNS two weeks later with device 
choice
Glucagon Stimulation Test
15 December 2012
Time GH
µg/L
Cortisol 
nmol/L
Glucose 
mmol/L
Bedside
Glucose 
mmol/L
0 5.9 187 3.5 4.2
60 4.23 525 3.0 3.7
90 4.4 374 3.2 4.1
120 2.4 269 3.0 3.6
150 3.13 227 2.9 3.4
180 3.24 223 2.7 3.4
GH devices

GH prescribing
• 4/52 prescription from the hospital
• CNS sends to relevant homecare company
• Letter to GP asking them to take on shared care, 
and continue prescribing of GH
• Patient will start around one month later
• VARIES FROM HOSPTIAL TO HOSPITAL
Patient journey
• From start to finish
AT LEAST TWO YEARS
POTENTIAL BARRIERS
o Missing clinic appointments
o Full clinics – delay in next appointment
o Waiting list for glucagon test
o Samples go missing
o Family indecisive re GH choice
• Want to come in again and see device
o Delay in prescription being done 
o Delay with health care company
o Funding requests from CCG
o GP refusal to prescribe
Discussion
• How do you think the patient journey for this child 
could have been made better?
• What factors do we need to consider before 
starting GH therapy in children?
Guidelines for GH therapy –
BEFORE starting
• Pubertal assessment and 
bone age
o Growth potential?
• Subnormal HV
• Pre-treatment HV
o HV after 1 year of treatment can 
be assessed
• Full commitment from 
family
• Involvement of CNS
o Counselling the child and family
o Assessing likelihood of 
compliance
o Patient choice of devices
o Teaching the daily injection
Guidelines for GH 
therapy - DURING
• Given subcutaneously in the evening, 7 days a 
week
• 4 monthly clinic visits
o Auxology and pubertal staging
• Compliance
• Home visit if HV disappointing
• 6-12 monthly IGF-1 measurement
o Dosage and compliance
• Annual bone age
• Discontinue GH at completion of 
growth (HV <2cm/yr)
• Re-test prior to transition
GHD - Children
• Due to the pituitary 
gland not being 
able to produce 
enough GH to 
facilitate the growth 
process
• Confirmed by a peak 
GH level below 20mU/L 
(7ng/ml)
o Short stature
o Slow growth
o Delayed bone age
Cancer treatment
Overall Late Effects of Brain Tumours
Late Effect Risk Factors Surveillance
Dental problems - Radiotherapy to field, including 
jaw (base of skull, cervical spine)
- Regular dental review
Hearing loss - Platinum chemotherapy
- +/- Radiotherapy to field, 
including middle ear (especially 
posterior fossa)
- Enquire re: speech and language 
development
Neuro-endocrine and growth -Tumours in area of hypothalamus 
or pituitary
- Cranial radiotherapy
-Regular anthropometric 
monitoring
-Regular endocrinology review
-Pituitary function tests
Secondary tumours -Radiotherapy
-Chemotherapy, particularly 
epipodophyllotoxins and 
alkylating agents
-Pre-disposing syndromes eg: NF1
-High index suspicions of skin 
lesions (especially skin cancers, 
meningiomas, glial tumours) 
within radiotherapy fields
-Patient education and regular 
examination of skin lesions
Shunts (blocked or infected) - Inform patient of potential 
complications and symptoms
Thyroid function - Radiotherapy to field, including 
thyroid (base of skull, cervical 
spine)
-Clinical screening
-Annual thyroid function tests
Alopecia - Radiotherapy to field including 
scalp
- Clinical examination
Hormone deficiencies..
• Most deficiencies are probably caused by the tumour 
itself, as much as surgery, radiotherapy or chemotherapy
• It can be difficult to know the exact causes and effects, 
but current research suggests..
Growth Hormone Deficiency
• The result of both tumour and radiotherapy
• Occurs more quickly after higher (rather 
than lower) radiation doses
• Older children, who’s growth and 
development is nearly finished, may get 
away without therapy in childhood
• The importance for it in adulthood is still 
under review:
o General health, muscle and bone strength, 
quality of life
Case study 2
Typical Paediatric
GHD?
History
• 17 year old boy – Tom
• 4 year history of fatigue
o Had swine flu age 13yrs, and ‘never regained energy’
o Complained of headaches, but ‘ignored as family history of migraines’
• Presented with a 6 week history of peripheral visual 
field loss – left, then right
Discussion
• Should Tom have been referred to an adult or a 
paediatric clinic?
• Diagnosis?
Brain MRI -
Craniopharyngioma
Brain MRI results
• Mostly cystic post-chiasmatic suprasellar mass, with 
a small solid calcified component anteriorly and on 
the right side.
• It elevates the anterior visual pathways and slightly 
favours the right side without eroding  through the 
floor of the third ventricle
• Appearances are typical of a craniopharyngioma
Craniopharyngioma
• Benign brain tumour
• Thought to form and 
grow from some 
misplaced cells in the 
brain close to the 
pituitary gland
• Presentation varies
o Most commonly occurring 
symptoms are headaches and 
blurred vision
Surgery
• 5 March 2014
o Cyst aspiration
• 12mls of fluid 
o Right sided ommaya
reservoir inserted
o Bi-temporal 
hemianopia 
recovered following 
surgery within 24 
hours
Ommaya reservoir
• Intraventricular
catheter system
o Can be used for 
aspiration of cerebro
spinal fluid (CSF), or 
delivery of drugs
o Indwelling catheter into 
one of the lateral 
ventricles in the brain
Post op endocrine 
assessment
• Insulin Tolerance Test 14 March 2014
• Intact pituitary reserve except severe 
growth hormone deficiency
• Good peak cortisol
• Normal thyroid function
• Normal gonadal function
• No diabetes insipidus
Insulin Tolerance Test -
results
• Growth hormone therapy 
commenced April 2014
• Nordipen 1.0mg daily s/c
Discussion
• Should Tom be starting GH?
• Paediatric or adult dose?
o Near end of puberty
o Minimal growth left
Neurosurgical follow up
• Post operative MRI scan
o Small solid component at the anterior wall of the cyst
o Intimately associated with the pituitary stalk, the carotid vessels and the 
optic chiasm
• Complete surgical excision would be difficult
o Either transphenoidal or transcranial
• Radiotherapy proposed
o April 2014 – Proton beam therapy, Jacksonville, Florida
• Tom too old under NHS guidance as over 16
o Family planned to raise funds for treatment in USA
o Eligible for clinical trial 
• Month of pre treatment tests = treatment paid for
Further post operative 
follow up
• 27 March 14
o Sperm cryopreservation
• 6 May 2014 - Florida
o Standard Short Synacthen Test
• Cortisol: 0840 180nmol/l → 0900 380nmol/l
• FT4 0.7ng/dl, TSH 0.7mIU/ml
• Commenced:
o Hydrocortisone (oral) 5mg three times a day
o Thyroxine (oral) 75mcg once a day
Proton beam treatment
• Type of external beam 
radiotherapy that uses 
ionizing radiation
• Tumour is targeted with a 
beam of protons
• Protons
o Damage the DNA of the cells, 
halting the reproduction
o Due to their large mass
• Little lateral side scatter in 
the tissue
• All have a certain range
o Very few go beyond 
that distance
• ? Overall benefit over 
conventional 
radiotherapy
Proton beam treatment
• May 17 2014 – July 9 2014
• 44 days of treatment
o 54 CGE (Gy) at 1.8 CGE per daily fraction
o Used a three field 3D conformal proton plan
Proton Beams
Proton beams
Post radiation patches 
(both sides)
Recommendations after 
Proton Therapy
• Neurocognitive testing
o Post treatment baseline
o Every 2/3 years minimum
• Neuroendocrine testing within 6 months
o Post treatment baseline
o Continue every 6/12 at least through puberty
• Ideally lifelong
o Pay particular attention to GH
• Ophthalmology and visual acuity
Endocrine follow up
• Back in the UK – July 2014
• Clinical Nurse Specialist review
o Growth hormone
o Thyroxine
o Hydrocortisone
• Intensive emergency management teaching
oMedic Alert bracelet
oOngoing with school
o Translations into Spanish
Emergency management
Tom..
• Continue neuropsyschological and 
ophthalmological assessments
o Good cognitive assessments
• A* at GCSEs
• A Levels in Barcelona
• University to study mechanical engineering
• GH discontinued February 2015
• No gonadotrophin deficiency, but Testosterone low 
normal level 
o USA: 320ng/dl (238 – 850)
• Hydrocortisone increased 7.5 / 5 / 5mg
• Family
o Increased support wanted  - Barcelona
Continuing plan
• Stay off growth hormone
o ? Start adult GH
• Encourage Thyroxine compliance
• Observe for evolving gonadotrophin
deficiency
• Continue annual 24 hour cortisol profiles
o ? Increase hydrocortisone to 10 / 5/ 5
• Transition – now nearly 19years old
Discussion
• What is the adult endocrine nursing approach with 
a ‘child’ such as Tom coming to your clinic?
Tom today
Conclusion
• Differing reasons why children may be GHD
• Very different patient journeys
• Food for thought at transition
